09:05 AM EDT, 10/16/2026 (MT Newswires) -- The European Medicines Agency's human medicines committee issued a positive opinion recommending a change to the terms of the marketing approval for Talvey, developed by Johnson & Johnson's (JNJ.F) Janssen-Cilag International. The recommendation covers the use of Talvey, in combination with daratumumab and pomalidomide or in combination with daratumumab, to treat adults with relapsed or refractory multiple myeloma who previously received at least one prior therapy, according to a Friday notice. The drug is indicated as monotherapy to treat adults with the condition who have received at least three therapies.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.